(Q37509262)

20 August 2017

1 reference

title

Moving toward new statin guidelines in a post-JUPITER world: principles to consider (English)

1 reference

20 August 2017

1

Paul M Ridker

1 reference

20 August 2017

publication date

1 July 2009

1 reference

Current Atherosclerosis Reports

20 August 2017

published in

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

4

1 reference

20 August 2017

page(s)

249-256

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-009-0039-1

20 August 2017

exact match

0 references

cites work

Calculating the number needed to treat for trials where the outcome is time to an event

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0039-1

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0039-1

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-009-0039-1

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Cost-minimization and the number needed to treat in uncomplicated hypertension

1 reference

12 December 2020

The immune response in atherosclerosis: a double-edged sword

1 reference

12 December 2020

CRP and statins for primary prevention of coronary artery disease

1 reference

12 December 2020

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

1 reference

12 December 2020

National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease

1 reference

12 December 2020

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

1 reference

12 December 2020

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

12 December 2020

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

1 reference

12 December 2020

C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany

1 reference

12 December 2020

C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003.

1 reference

12 December 2020

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

12 December 2020

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

1 reference

12 December 2020

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

12 December 2020

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

1 reference

12 December 2020

Beta-blockers for hypertension

1 reference

12 December 2020

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

1 reference

12 December 2020

Inflammatory markers and the risk of coronary heart disease in men and women

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

C-reactive protein levels and outcomes after statin therapy

1 reference

12 December 2020

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

1 reference

12 December 2020

Gauging the impact of statins using number needed to treat

1 reference

12 December 2020

A surgical safety checklist to reduce morbidity and mortality in a global population

1 reference

12 December 2020

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

12 December 2020

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

12 December 2020

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

12 December 2020

Biomarkers of cardiovascular disease: molecular basis and practical considerations

1 reference

12 December 2020

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

10.1007/S11883-009-0039-1

Identifiers

DOI

1 reference

20 August 2017

1 reference